|Videos|March 9, 2021

COVID-19 and Viral Suppression

During the pandemic, reduced HIV testing led to concerns about getting people diagnosed and on antiretroviral therapy (ART), and achieving viral suppression (VS).

Early on in the pandemic, in the southern United States, HIV testing sites shut down, and concerns about contracting COVID-19 kept people from getting tested, acknowledged Aadia Rana, MD, associate professor of Medicine at the University of Alabama-Birmingham and an associate scientist with the UAB Center for AIDS Research.

During this period, health care providers were concerned that a lack of testing could lead to untreated cases and prevent access to necessary ART to work towards viral suppression. While anecdotal evidence suggests this was mostly a temporary trend, COVID-19 is a reminder there are other ongoing challenges to HIV care adherence.

Rana’s focus has been studying viral suppression. She makes an important distinction between achieving it and making it last.

“If we are truly going to end the epidemic, we need to achieve much higher rates of not just achieving viral suppression but sustained viral suppression,” Rana said.

In an earlier interview with Contagion, Rana discussed her study’s findings looking at time to VS in Alabama, Louisiana, and Mississippi.

Those findings were presented during the Conference on Retroviruses and Opportunistic Infections (CROI) 2021 virtual sessions.

In their follow-up studies, Rana and her colleagues are going to be looking at sustainable viral suppression trends from a longitudinal approach.

“We need to analyze—at the community level—some of the informants of achieving viral suppression and sustaining viral suppression,” Rana said.

She also wants to study how the pandemic affected the time to VS.

In this second interview segment with Contagion, Rana discusses the positive results in seeing the downward trend to VS and what was seen in the south during the pandemic.


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.